Skip to main content
Premium Trial:

Request an Annual Quote

Rosetta Genomics Dispute With Genoptix Places Pending Merger in Jeopardy

NEW YORK (GenomeWeb) – Rosetta Genomics said today that its previously announced merger with Genoptix may not occur due to a dispute between the companies.

If the transaction is not completed by the end of the day, Rosetta said it intends to file for bankruptcy protection in the US and Israel where it maintains operations.

In late 2017, Genoptix agreed to acquire Rosetta for $10 million in cash, but the deal was scuttled earlier this year after failing to generate enough support from Rosetta's shareholders. Shortly thereafter, the companies signed a new merger agreement — which valued Rosetta at $9 million — that was ultimately approved by Rosetta's shareholders.

While that new deal was supposed to close on May 27, Rosetta disclosed today that Genoptix has "refused to provide assurances that it intends to complete the transaction" due to an undisclosed "material adverse effect" affecting Rosetta, as well as breaches of representations and warranties.

These issues would eliminate Genoptix's obligation to complete the merger, though Rosetta said it disputes them.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.